A Long-Term, Open-Label, Phase 3a Safety Study of Oral TAK-559 (32 mg QD) in the Treatment of Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Imiglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Takeda Global Research and Development Center
- 10 Jun 2017 Biomarkers information updated
- 18 Dec 2008 Actual end date (Dec 2004) added as reported by ClinicalTrials.gov.
- 15 Oct 2008 New trial record.